Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Inclusion Criteria: * Histologically documented Classical Hodgkin's lymphoma that is recurrent or refractory after standard chemotherapy; core biopsies are acceptable if they contain adequate tissue for primary diagnosis and immunophenotyping; bone marrow biopsies as the sole means of diagnosis are not acceptable * Patients with Hodgkin's lymphoma may have one of the following World Health Organization subtypes: * Nodular sclerosis Hodgkin's lymphoma * Lymphocyte-rich Hodgkin's lymphoma * Mixed cellularity Hodgkin's lymphoma * Lymphocyte depletion Hodgkin's lymphoma * Nodular lymphocyte predominant Hodgkin's lymphoma * Patients must have relapsed or progressed after at least one prior therapy * Patients with relapsed or refractory disease following stem cell transplantation are permitted * No prior treatment with bendamustine; prior therapy with gemcitabine is permitted * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 * Measurable disease must be present either on physical examination or imaging studies; non-measurable disease alone is not acceptable * Measurable disease: lesions that can be accurately measured in at least two dimensions as \>= 1.0 x 1.0 cm by computerized tomography (CT), PET/CT (positron emission tomography/CT), or magnetic resonance imaging (MRI) * Non-measurable disease: all other lesions, including small lesions (less than 1.0 x 1.0 cm) and truly non-measurable lesions; lesions that are considered non-measurable include the …